BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31167547)

  • 1. Emerging Treatments and Novel Pathways in Pruritus.
    Besner Morin C; Misery L
    J Cutan Med Surg; 2019; 23(5):528-536. PubMed ID: 31167547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs on the Horizon for Chronic Pruritus.
    McEwen MW; Fite EM; Yosipovitch G; Patel T
    Dermatol Clin; 2018 Jul; 36(3):335-344. PubMed ID: 29929605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Itch Management: Treatments under Development.
    Pereira MP; Ständer S
    Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
    Soeberdt M; Kilic A; Abels C
    Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
    Ständer S; Yosipovitch G
    Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upcoming topical TRPV1 anti-pruritic compounds.
    Lee KP; Koshelev MV
    Dermatol Online J; 2020 Sep; 26(9):. PubMed ID: 33054935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeic acid exhibits anti-pruritic effects by inhibition of multiple itch transmission pathways in mice.
    Pradhananga S; Shim WS
    Eur J Pharmacol; 2015 Sep; 762():313-21. PubMed ID: 26057691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of itch and new treatments.
    Raap U; Ständer S; Metz M
    Curr Opin Allergy Clin Immunol; 2011 Oct; 11(5):420-7. PubMed ID: 21772138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical capsaicin. The fire of a 'hot' medicine is reignited.
    Papoiu AD; Yosipovitch G
    Expert Opin Pharmacother; 2010 Jun; 11(8):1359-71. PubMed ID: 20446852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrogen sulfide donors alleviate itch secondary to the activation of type-2 protease activated receptors (PAR-2) in mice.
    Coavoy-Sánchez SA; Rodrigues L; Teixeira SA; Soares AG; Torregrossa R; Wood ME; Whiteman M; Costa SKP; Muscará MN
    Pharmacol Res; 2016 Nov; 113(Pt A):686-694. PubMed ID: 27720932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Itch associated with skin disease: advances in pathophysiology and emerging therapies.
    Yosipovitch G; Fleischer A
    Am J Clin Dermatol; 2003; 4(9):617-22. PubMed ID: 12926980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Itch Management: Systemic Agents.
    Pongcharoen P; Fleischer AB
    Curr Probl Dermatol; 2016; 50():46-53. PubMed ID: 27578071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic advances in the systemic treatment of itch.
    Summey BT; Yosipovitch G
    Dermatol Ther; 2005; 18(4):328-32. PubMed ID: 16297005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprepitant for the Treatment of Chronic Refractory Pruritus.
    He A; Alhariri JM; Sweren RJ; Kwatra MM; Kwatra SG
    Biomed Res Int; 2017; 2017():4790810. PubMed ID: 29057261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Itch in Atopic Dermatitis Management.
    Kamata Y; Tominaga M; Takamori K
    Curr Probl Dermatol; 2016; 50():86-93. PubMed ID: 27578076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Itch sensation through transient receptor potential channels: a systematic review and relevance to manual therapy.
    Lucaciu OC; Connell GP
    J Manipulative Physiol Ther; 2013; 36(6):385-93. PubMed ID: 23896168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
    Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
    BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.
    Zic JA; Straka BT; McGirt LY; Nian H; Yu C; Brown NJ
    JAMA Dermatol; 2018 Oct; 154(10):1221-1222. PubMed ID: 30140912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
    Santini D; Vincenzi B; Guida FM; Imperatori M; Schiavon G; Venditti O; Frezza AM; Berti P; Tonini G
    Lancet Oncol; 2012 Oct; 13(10):1020-4. PubMed ID: 22995650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurokinin 1 Receptor Antagonists for Pruritus.
    Alam M; Buddenkotte J; Ahmad F; Steinhoff M
    Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.